Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

Illumina is one of Mainboard-listed Venture Corporation’s major customers. Illumina’s shares have fallen some 26.4% over the ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an ...

Genomics company Illumina (NASDAQ:ILMN) reported Q4 CY2024 results , but sales were flat year on year at $1.1 billion. On the ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in ...